BioSpace News Archive

Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced the publication, in the Journal of Clinical Chemistry, of the final results of the multicenter DETECT III clinical trial.

GSK plc and Aiolos Bio, Inc. announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.

Cardinal Health (NYSE:CAH) today announced progress on the company’s ongoing business and portfolio review, including an updated enterprise operating and segment reporting structure, and an update to its fiscal year 2024 non-GAAP diluted earnings per share (EPS) outlook.

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, released its Dealmakers’ Intentions Survey.

Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Kraig Biocraft Laboratories, Inc. announces its Vietnamese subsidiary, Prodigy Textiles, has joined the Vietnam Sericulture Association.

MediWound Ltd. today announced that the U.S. Food and Drug Administration (FDA) has completed their filing review and accepted a supplement to the NexoBrid® biologics license application (sBLA) for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns.

Today, the company announced the appointment of Mark J. Alles, TORL’s Executive Chairman, as the company’s new Chairman and CEO.

Faron Pharmaceuticals Ltd. announced that the first patient has been dosed in Phase 2 of the BEXMAB trial that evaluates the safety and efficacy of bexmarilimab, in combination with standard of care in patients with hypomethylating agents -refractory or relapsed myelodysplastic syndrome, an aggressive myeloid leukemia with very few treatment options.

Ono Pharmaceutical Co., Ltd. informed that it has started a new collaboration with BioMed X on cancer immunotherapies and has been inviting researchers who are interested in this research project via BioMed X.